Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Analysts have set a 12 month consensus price target of $11.00 for the company and are expecting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also given Organogenesis an industry rank of 88 out of 256 based on the ratings given to related companies.
ORGO has been the topic of several research reports. BTIG Research initiated coverage on shares of Organogenesis in a report on Friday, April 12th. They set a “buy” rating and a $12.00 price target on the stock. Credit Suisse Group began coverage on shares of Organogenesis in a research report on Thursday, May 2nd. They issued an “outperform” rating and a $9.00 price target on the stock. CIBC began coverage on shares of Organogenesis in a research report on Wednesday, April 17th. They issued an “outperform” rating and a $11.00 price target on the stock. Oppenheimer began coverage on shares of Organogenesis in a research report on Wednesday, April 17th. They issued an “outperform” rating and a $11.00 price target on the stock. Finally, SunTrust Banks began coverage on shares of Organogenesis in a research report on Thursday, April 11th. They issued a “buy” rating and a $11.00 price target on the stock.
Shares of NASDAQ:ORGO traded up $0.02 during midday trading on Thursday, hitting $7.02. The stock had a trading volume of 107,708 shares, compared to its average volume of 103,803. Organogenesis has a fifty-two week low of $6.28 and a fifty-two week high of $310.90.
Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.
Further Reading: Dividend
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.